Abstract Body

Background

In adults, dolutegravir (DTG)-based antiretroviral therapy (ART) has been linked with excess weight gain. However, pediatric data remain limited and inconsistent. We examined growth trajectories, measured by BMI-for-age z-scores (zBMI), among children and adolescents living with HIV (CALHIV) initiating DTG. 

Methods

CALHIV aged 1 month–19 years from the International epidemiology Databases to Evaluate AIDS (IeDEA) cohorts in West, East, Central, and Southern Africa, the Asia-Pacific, and Latin America and the Caribbean were included if they initiated DTG from 2019 onwards, and had ≥1 anthropometric measurement within 96 weeks (wks) of DTG initiation. Linear mixed-effects models with linear splines were used to compare zBMI across three periods (0–48 wks before, 0–48 wks after, 48–96 wks after DTG initiation), adjusting for demographic and clinical variables.

Results

Overall, 29,144 CALHIV were included, 54% were female; 50% were from Southern Africa. At DTG start, median age was 12.8 years (Interquartile Range [IQR] 9.2–15.9), median zBMI was –0.60 (IQR –1.44 to 0.17); 1.5% were overweight/obese (zBMI >2). Overall, estimated mean zBMI increased by 0.13 [95%CI 0.02–0.24] in the 48 wks before DTG vs 0.19 [0.09–0.30] in the 48 wks after, but declined to –0.02 [–0.25 to 0.21] by 96 wks. By regimen, ART-naïve CALHIV starting DTG with tenofovir alafenamide (TAF) had the steepest initial gain (48 wks before: 0.16 [–0.13 to 0.43] vs 48 wks after: 0.56 [0.44–0.68], p=0.017), followed by a decline (48-96 wks after: –0.16 [–0.41 to 0.08]), compared to naïve or non-naïve CALHIV starting with other nucleoside reverse transcriptase inhibitors. Those with advanced immunosuppression also showed sharp early gains on DTG (48 wks before: 0.17 [–0.04 to 0.39] vs 48 wks after 0.83 [0.67–0.98], p<0.001), followed by a decline (48-96 wks after: –0.47 [–0.77 to –0.16]), compared to those with stable immunological status. Viral load at DTG initiation was not significantly associated with zBMI evolution.

Conclusions

In this global cohort of CALHIV, DTG initiation was followed by modest zBMI gains, which was more pronounced in those with poor immunological status or DTG+TAF exposure, with plateau or decline by year two. The pattern suggests “return-to-health” rather than sustained excess weight gain. These findings support DTG use in CALHIV but highlight the need for further study of long-term metabolic outcomes in specific subgroups.

Table or Figure